UA81382C2

UA81382C2 - Composition for treating retinol-related diseases by modulation of retinol binding

Composition for treating retinol-related diseases by modulation of retinol binding Download PDF

Info

Publication number: UA81382C2
Authority: UA; Ukraine
Prior art keywords: compound; kvr; retinol; mammal; group
Prior art date: 2005-07-11

Application number

UAA200704499A

Other languages

English (en)

Ukrainian (uk)

Priority date

2005-07-11

Filing date

2005-07-12

Publication date

2007-12-25

2005-07-12 Application filed filed Critical

2005-12-07 Priority claimed from PCT/US2005/044416 external-priority patent/WO2006063128A2/en

2007-12-25 Publication of UA81382C2 publication Critical patent/UA81382C2/uk

Links

FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 title claims abstract description 291
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 title claims abstract description 168
239000011607 retinol Substances 0.000 title claims abstract description 128
229960003471 retinol Drugs 0.000 title claims abstract description 128
239000000203 mixture Substances 0.000 title claims abstract description 127
235000020944 retinol Nutrition 0.000 title claims abstract description 125
230000027455 binding Effects 0.000 title claims description 138
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 65
201000010099 disease Diseases 0.000 title abstract description 48
239000003795 chemical substances by application Substances 0.000 claims abstract description 181
208000002780 macular degeneration Diseases 0.000 claims abstract description 94
238000011282 treatment Methods 0.000 claims abstract description 46
239000003814 drug Substances 0.000 claims abstract description 40
206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 27
150000001875 compounds Chemical class 0.000 claims description 250
241000124008 Mammalia Species 0.000 claims description 248
239000000556 agonist Substances 0.000 claims description 208
239000003112 inhibitor Substances 0.000 claims description 88
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 41
239000003963 antioxidant agent Substances 0.000 claims description 41
235000006708 antioxidants Nutrition 0.000 claims description 41
230000003078 antioxidant effect Effects 0.000 claims description 34
239000002207 metabolite Substances 0.000 claims description 34
235000021466 carotenoid Nutrition 0.000 claims description 32
150000001747 carotenoids Chemical class 0.000 claims description 32
229940100552 retinamide Drugs 0.000 claims description 27
239000012634 fragment Substances 0.000 claims description 24
239000002260 anti-inflammatory agent Substances 0.000 claims description 23
229940121363 anti-inflammatory agent Drugs 0.000 claims description 23
230000010030 glucose lowering effect Effects 0.000 claims description 23
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 22
125000003118 aryl group Chemical group 0.000 claims description 22
229940079593 drug Drugs 0.000 claims description 22
229910052500 inorganic mineral Inorganic materials 0.000 claims description 22
239000011707 mineral Substances 0.000 claims description 22
150000003904 phospholipids Chemical class 0.000 claims description 22
238000004519 manufacturing process Methods 0.000 claims description 21
239000000411 inducer Substances 0.000 claims description 20
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 19
229940011871 estrogen Drugs 0.000 claims description 19
239000000262 estrogen Substances 0.000 claims description 19
239000000651 prodrug Substances 0.000 claims description 19
229940002612 prodrug Drugs 0.000 claims description 19
125000001424 substituent group Chemical group 0.000 claims description 19
239000000126 substance Substances 0.000 claims description 18
230000001225 therapeutic effect Effects 0.000 claims description 18
239000012453 solvate Substances 0.000 claims description 16
208000035719 Maculopathy Diseases 0.000 claims description 15
238000002347 injection Methods 0.000 claims description 12
239000007924 injection Substances 0.000 claims description 12
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
208000007014 Retinitis pigmentosa Diseases 0.000 claims description 10
230000000692 anti-sense effect Effects 0.000 claims description 10
125000003107 substituted aryl group Chemical group 0.000 claims description 10
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 9
230000003579 anti-obesity Effects 0.000 claims description 9
125000000623 heterocyclic group Chemical group 0.000 claims description 9
229940088597 hormone Drugs 0.000 claims description 9
239000005556 hormone Substances 0.000 claims description 9
125000006709 (C5-C7) cycloalkenyl group Chemical group 0.000 claims description 8
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
238000010521 absorption reaction Methods 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
208000008069 Geographic Atrophy Diseases 0.000 claims description 7
230000009885 systemic effect Effects 0.000 claims description 7
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
230000002440 hepatic effect Effects 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 5
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 4
102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 4
229940124073 Complement inhibitor Drugs 0.000 claims description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
239000004074 complement inhibitor Substances 0.000 claims description 4
125000005843 halogen group Chemical group 0.000 claims description 4
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 3
ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims description 3
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 3
229940123208 Biguanide Drugs 0.000 claims description 3
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 3
102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims description 3
229930193140 Neomycin Natural products 0.000 claims description 3
101100129345 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mae2 gene Proteins 0.000 claims description 3
229940100389 Sulfonylurea Drugs 0.000 claims description 3
229940123464 Thiazolidinedione Drugs 0.000 claims description 3
230000036528 appetite Effects 0.000 claims description 3
235000019789 appetite Nutrition 0.000 claims description 3
239000002830 appetite depressant Substances 0.000 claims description 3
102000030904 bile acid binding Human genes 0.000 claims description 3
108091022863 bile acid binding Proteins 0.000 claims description 3
239000003833 bile salt Substances 0.000 claims description 3
229960001767 dextrothyroxine Drugs 0.000 claims description 3
235000003642 hunger Nutrition 0.000 claims description 3
229950004994 meglitinide Drugs 0.000 claims description 3
229960004927 neomycin Drugs 0.000 claims description 3
229960003512 nicotinic acid Drugs 0.000 claims description 3
235000001968 nicotinic acid Nutrition 0.000 claims description 3
239000011664 nicotinic acid Substances 0.000 claims description 3
229960003912 probucol Drugs 0.000 claims description 3
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims description 3
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 3
206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
102100024295 Maltase-glucoamylase Human genes 0.000 claims description 2
206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
108010028144 alpha-Glucosidases Proteins 0.000 claims description 2
239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 2
229920005989 resin Polymers 0.000 claims description 2
239000011347 resin Substances 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims 3
241000251468 Actinopterygii Species 0.000 claims 2
229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
101001090074 Homo sapiens Small nuclear protein PRAC1 Proteins 0.000 claims 1
102100034766 Small nuclear protein PRAC1 Human genes 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
230000009977 dual effect Effects 0.000 claims 1
238000000034 method Methods 0.000 abstract description 158
108090000623 proteins and genes Proteins 0.000 abstract description 41
102000029752 retinol binding Human genes 0.000 abstract description 26
108091000053 retinol binding Proteins 0.000 abstract description 26
238000002560 therapeutic procedure Methods 0.000 abstract description 24
102000004169 proteins and genes Human genes 0.000 abstract description 23
108010071690 Prealbumin Proteins 0.000 abstract description 16
102000009190 Transthyretin Human genes 0.000 abstract description 16
229940124597 therapeutic agent Drugs 0.000 abstract description 16
201000010934 exostosis Diseases 0.000 abstract description 11
201000010930 hyperostosis Diseases 0.000 abstract description 11
238000003556 assay Methods 0.000 abstract description 10
208000030159 metabolic disease Diseases 0.000 abstract description 6
208000018127 Idiopathic intracranial hypertension Diseases 0.000 abstract description 5
230000002776 aggregation Effects 0.000 abstract description 5
238000004220 aggregation Methods 0.000 abstract description 5
208000001381 pseudotumor cerebri Diseases 0.000 abstract description 5
230000002265 prevention Effects 0.000 abstract description 2
238000009097 single-agent therapy Methods 0.000 abstract 1
239000005557 antagonist Substances 0.000 description 174
102100036109 Dual specificity protein kinase TTK Human genes 0.000 description 165
230000000694 effects Effects 0.000 description 126
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 70
-1 small molecule compound Chemical class 0.000 description 60
230000014616 translation Effects 0.000 description 53
108091023037 Aptamer Proteins 0.000 description 52
238000013519 translation Methods 0.000 description 51
238000013518 transcription Methods 0.000 description 45
230000035897 transcription Effects 0.000 description 45
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 43
230000015572 biosynthetic process Effects 0.000 description 42
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 40
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 40
235000019155 vitamin A Nutrition 0.000 description 40
239000011719 vitamin A Substances 0.000 description 40
229940045997 vitamin a Drugs 0.000 description 40
125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 39
102000053642 Catalytic RNA Human genes 0.000 description 38
108090000994 Catalytic RNA Proteins 0.000 description 38
229960003957 dexamethasone Drugs 0.000 description 38
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 38
108091092562 ribozyme Proteins 0.000 description 38
239000005495 thyroid hormone Substances 0.000 description 37
229940036555 thyroid hormone Drugs 0.000 description 37
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 36
AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 35
241000699670 Mus sp. Species 0.000 description 35
229960003604 testosterone Drugs 0.000 description 35
210000004027 cell Anatomy 0.000 description 34
206010012601 diabetes mellitus Diseases 0.000 description 31
235000020945 retinal Nutrition 0.000 description 29
230000002207 retinal effect Effects 0.000 description 28
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
239000011604 retinal Substances 0.000 description 26
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 26
239000000074 antisense oligonucleotide Substances 0.000 description 25
238000012230 antisense oligonucleotides Methods 0.000 description 25
210000002966 serum Anatomy 0.000 description 25
229930003935 flavonoid Natural products 0.000 description 24
150000002215 flavonoids Chemical class 0.000 description 24
235000017173 flavonoids Nutrition 0.000 description 24
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 24
NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 24
210000001519 tissue Anatomy 0.000 description 24
108020000948 Antisense Oligonucleotides Proteins 0.000 description 23
108020004999 messenger RNA Proteins 0.000 description 23
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 23
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
230000009286 beneficial effect Effects 0.000 description 21
229960001259 diclofenac Drugs 0.000 description 21
229950003662 fenretinide Drugs 0.000 description 21
239000002371 cardiac agent Substances 0.000 description 20
230000014509 gene expression Effects 0.000 description 20
230000002124 endocrine Effects 0.000 description 19
239000003668 hormone analog Substances 0.000 description 19
239000000816 peptidomimetic Substances 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
102000014914 Carrier Proteins Human genes 0.000 description 18
239000000328 estrogen antagonist Substances 0.000 description 18
229960003387 progesterone Drugs 0.000 description 18
239000000186 progesterone Substances 0.000 description 18
235000018102 proteins Nutrition 0.000 description 18
208000035475 disorder Diseases 0.000 description 17
239000000044 progesterone antagonist Substances 0.000 description 17
239000004475 Arginine Substances 0.000 description 16
241000282414 Homo sapiens Species 0.000 description 16
102000030914 Fatty Acid-Binding Human genes 0.000 description 15
108091008324 binding proteins Proteins 0.000 description 15
108091022862 fatty acid binding Proteins 0.000 description 15
229940076372 protein antagonist Drugs 0.000 description 15
210000001525 retina Anatomy 0.000 description 15
230000000007 visual effect Effects 0.000 description 15
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 14
150000004945 aromatic hydrocarbons Chemical class 0.000 description 14
230000007423 decrease Effects 0.000 description 14
230000006870 function Effects 0.000 description 14
102000039446 nucleic acids Human genes 0.000 description 14
108020004707 nucleic acids Proteins 0.000 description 14
150000007523 nucleic acids Chemical class 0.000 description 14
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 14
102000004877 Insulin Human genes 0.000 description 13
108090001061 Insulin Proteins 0.000 description 13
230000004438 eyesight Effects 0.000 description 13
229940125396 insulin Drugs 0.000 description 13
FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 12
208000027073 Stargardt disease Diseases 0.000 description 12
238000001514 detection method Methods 0.000 description 12
210000002381 plasma Anatomy 0.000 description 12
108090000765 processed proteins & peptides Proteins 0.000 description 12
201000004569 Blindness Diseases 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
WKYDOCGICAMTKE-NBIQJRODSA-N n-ethyl retinamide Chemical compound CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C WKYDOCGICAMTKE-NBIQJRODSA-N 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 11
208000024891 symptom Diseases 0.000 description 11
229940034208 thyroxine Drugs 0.000 description 11
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 11
AKJHMTWEGVYYSE-DRYRGIGMSA-N (2z,4e,6e,8e)-n-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-DRYRGIGMSA-N 0.000 description 10
102000002274 Matrix Metalloproteinases Human genes 0.000 description 10
108010000684 Matrix Metalloproteinases Proteins 0.000 description 10
241000700159 Rattus Species 0.000 description 10
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 10
230000008901 benefit Effects 0.000 description 10
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 10
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
150000004492 retinoid derivatives Chemical class 0.000 description 10
238000001356 surgical procedure Methods 0.000 description 10
238000012360 testing method Methods 0.000 description 10
229960001727 tretinoin Drugs 0.000 description 10
SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 9
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 9
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 9
230000002159 abnormal effect Effects 0.000 description 9
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 9
229960005370 atorvastatin Drugs 0.000 description 9
201000006754 cone-rod dystrophy Diseases 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
239000002243 precursor Substances 0.000 description 9
NCYCYZXNIZJOKI-HPNHMNAASA-N 11Z-retinal Natural products CC(=C/C=O)C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-HPNHMNAASA-N 0.000 description 8
102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 8
108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 8
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 8
102000010175 Opsin Human genes 0.000 description 8
108050001704 Opsin Proteins 0.000 description 8
201000007737 Retinal degeneration Diseases 0.000 description 8
239000002253 acid Substances 0.000 description 8
229960001445 alitretinoin Drugs 0.000 description 8
239000012491 analyte Substances 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000001656 lutein Substances 0.000 description 8
229960005375 lutein Drugs 0.000 description 8
108091008695 photoreceptors Proteins 0.000 description 8
230000008569 process Effects 0.000 description 8
150000003384 small molecules Chemical class 0.000 description 8
230000005945 translocation Effects 0.000 description 8
230000004393 visual impairment Effects 0.000 description 8
JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 7
SHGAZHPCJJPHSC-JPXMXQIXSA-N 11-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-JPXMXQIXSA-N 0.000 description 7
208000024827 Alzheimer disease Diseases 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 7
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 7
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 7
JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 7
QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 7
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 7
JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 7
239000011717 all-trans-retinol Substances 0.000 description 7
206010002022 amyloidosis Diseases 0.000 description 7
239000004037 angiogenesis inhibitor Substances 0.000 description 7
235000013734 beta-carotene Nutrition 0.000 description 7
239000011648 beta-carotene Substances 0.000 description 7
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 7
229960002747 betacarotene Drugs 0.000 description 7
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 7
229960005110 cerivastatin Drugs 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000006378 damage Effects 0.000 description 7
229960003765 fluvastatin Drugs 0.000 description 7
239000008103 glucose Substances 0.000 description 7
229960004844 lovastatin Drugs 0.000 description 7
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 7
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 7
235000012680 lutein Nutrition 0.000 description 7
KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 7
ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 7
229960002965 pravastatin Drugs 0.000 description 7
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
239000000523 sample Substances 0.000 description 7
238000012216 screening Methods 0.000 description 7
229960002855 simvastatin Drugs 0.000 description 7
239000000758 substrate Substances 0.000 description 7
FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 7
235000010930 zeaxanthin Nutrition 0.000 description 7
239000001775 zeaxanthin Substances 0.000 description 7
229940043269 zeaxanthin Drugs 0.000 description 7
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000005711 Benzoic acid Substances 0.000 description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
206010025421 Macule Diseases 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
102000004330 Rhodopsin Human genes 0.000 description 6
108090000820 Rhodopsin Proteins 0.000 description 6
229930003427 Vitamin E Natural products 0.000 description 6
235000010233 benzoic acid Nutrition 0.000 description 6
WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 6
210000004204 blood vessel Anatomy 0.000 description 6
239000010949 copper Substances 0.000 description 6
230000002950 deficient Effects 0.000 description 6
230000007850 degeneration Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
230000003828 downregulation Effects 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
210000003494 hepatocyte Anatomy 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
230000035772 mutation Effects 0.000 description 6
239000000049 pigment Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
230000004258 retinal degeneration Effects 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
210000001138 tear Anatomy 0.000 description 6
229960002117 triamcinolone acetonide Drugs 0.000 description 6
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 6
235000019165 vitamin E Nutrition 0.000 description 6
239000011709 vitamin E Substances 0.000 description 6
229940046009 vitamin E Drugs 0.000 description 6
OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 5
VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 5
125000006530 (C4-C6) alkyl group Chemical group 0.000 description 5
VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 5
LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 5
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
229960001770 atorvastatin calcium Drugs 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000009918 complex formation Effects 0.000 description 5
229950003040 dalvastatin Drugs 0.000 description 5
HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 5
VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 description 5
230000009368 gene silencing by RNA Effects 0.000 description 5
238000001415 gene therapy Methods 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000003914 insulin secretion Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
229960005280 isotretinoin Drugs 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 5
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 5
229950009116 mevastatin Drugs 0.000 description 5
230000008929 regeneration Effects 0.000 description 5
238000011069 regeneration method Methods 0.000 description 5
235000021283 resveratrol Nutrition 0.000 description 5
229940016667 resveratrol Drugs 0.000 description 5
229930002330 retinoic acid Natural products 0.000 description 5
108010066034 retinol binding protein receptor Proteins 0.000 description 5
150000004609 retinol derivatives Chemical class 0.000 description 5
229960000672 rosuvastatin Drugs 0.000 description 5
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
230000002103 transcriptional effect Effects 0.000 description 5
239000011701 zinc Substances 0.000 description 5
229910052725 zinc Inorganic materials 0.000 description 5
ILYSIVSSNXQZQG-OVSJKPMPSA-N (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-amine Chemical class NC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C ILYSIVSSNXQZQG-OVSJKPMPSA-N 0.000 description 4
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
206010022489 Insulin Resistance Diseases 0.000 description 4
208000017442 Retinal disease Diseases 0.000 description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
239000004098 Tetracycline Substances 0.000 description 4
241000251539 Vertebrata <Metazoa> Species 0.000 description 4
229930003268 Vitamin C Natural products 0.000 description 4
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 4
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
239000002585 base Substances 0.000 description 4
239000012472 biological sample Substances 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
239000002738 chelating agent Substances 0.000 description 4
239000005515 coenzyme Substances 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000002596 correlated effect Effects 0.000 description 4
230000002354 daily effect Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000008021 deposition Effects 0.000 description 4
TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
239000000284 extract Substances 0.000 description 4
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 4
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
238000006317 isomerization reaction Methods 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
229960003424 phenylacetic acid Drugs 0.000 description 4
230000000649 photocoagulation Effects 0.000 description 4
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
238000009256 replacement therapy Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
210000003583 retinal pigment epithelium Anatomy 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
235000019364 tetracycline Nutrition 0.000 description 4
150000003522 tetracyclines Chemical class 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
235000019154 vitamin C Nutrition 0.000 description 4
239000011718 vitamin C Substances 0.000 description 4
FPIPGXGPPPQFEQ-HPNHMNAASA-N 11-cis-retinol Natural products OCC=C(C)C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-HPNHMNAASA-N 0.000 description 3
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
201000005932 Alstrom Syndrome Diseases 0.000 description 3
101000640990 Arabidopsis thaliana Tryptophan-tRNA ligase, chloroplastic/mitochondrial Proteins 0.000 description 3
108010078791 Carrier Proteins Proteins 0.000 description 3
HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 3
101000720524 Gordonia sp. (strain TY-5) Acetone monooxygenase (methyl acetate-forming) Proteins 0.000 description 3
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
229940124761 MMP inhibitor Drugs 0.000 description 3
102000005741 Metalloproteases Human genes 0.000 description 3
108010006035 Metalloproteases Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
BVMWIXWOIGJRGE-UHFFFAOYSA-N NP(O)=O Chemical compound NP(O)=O BVMWIXWOIGJRGE-UHFFFAOYSA-N 0.000 description 3
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
108010025020 Nerve Growth Factor Proteins 0.000 description 3
102000007072 Nerve Growth Factors Human genes 0.000 description 3
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
108010081996 Photosystem I Protein Complex Proteins 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
206010038923 Retinopathy Diseases 0.000 description 3
102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 3
108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 3
241000251131 Sphyrna Species 0.000 description 3
UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 3
UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 3
108010048889 Thyroxine-Binding Proteins Proteins 0.000 description 3
102000009488 Thyroxine-Binding Proteins Human genes 0.000 description 3
102000002501 Tryptophan-tRNA Ligase Human genes 0.000 description 3
206010047571 Visual impairment Diseases 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000009471 action Effects 0.000 description 3
238000001467 acupuncture Methods 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
150000004347 all-trans-retinol derivatives Chemical class 0.000 description 3
229940019834 apocarotenal Drugs 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
150000001746 carotenes Chemical class 0.000 description 3
235000005473 carotenes Nutrition 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 3
229960002173 citrulline Drugs 0.000 description 3
235000013477 citrulline Nutrition 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
229960005537 combretastatin A-4 Drugs 0.000 description 3
HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
229960000616 diflunisal Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
229960001347 fluocinolone acetonide Drugs 0.000 description 3
238000002513 implantation Methods 0.000 description 3
229960000905 indomethacin Drugs 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
208000018769 loss of vision Diseases 0.000 description 3
231100000864 loss of vision Toxicity 0.000 description 3
238000005259 measurement Methods 0.000 description 3
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 3
229960003248 mifepristone Drugs 0.000 description 3
210000003097 mucus Anatomy 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229960003104 ornithine Drugs 0.000 description 3
230000011164 ossification Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000002428 photodynamic therapy Methods 0.000 description 3
210000000608 photoreceptor cell Anatomy 0.000 description 3
150000003071 polychlorinated biphenyls Chemical class 0.000 description 3
229960004618 prednisone Drugs 0.000 description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
208000022256 primary systemic amyloidosis Diseases 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 3
238000010791 quenching Methods 0.000 description 3
230000000171 quenching effect Effects 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
210000003296 saliva Anatomy 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
229950001248 squalamine Drugs 0.000 description 3
238000009168 stem cell therapy Methods 0.000 description 3
238000009580 stem-cell therapy Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
229960000894 sulindac Drugs 0.000 description 3
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229960002180 tetracycline Drugs 0.000 description 3
229930101283 tetracycline Natural products 0.000 description 3
208000029257 vision disease Diseases 0.000 description 3
150000003722 vitamin derivatives Chemical class 0.000 description 3
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
AMNXBQPRODZJQR-DITALETJSA-N (2s)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-n-[(1r)-2-hydroxy-1-phenylethyl]acetamide Chemical compound C1([C@@H](C=2C=CC=C(C=2)CN2C3=CC=CC=C3C3=C(C)C=C(N=C32)C)C(=O)N[C@@H](CO)C=2C=CC=CC=2)CCCC1 AMNXBQPRODZJQR-DITALETJSA-N 0.000 description 2
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
ACLBTXLOASZGRX-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-n,n-diethylethanamine;hydrochloride Chemical class Cl.O1CCOC2=C1C=CC=C2OCCN(CC)CC ACLBTXLOASZGRX-UHFFFAOYSA-N 0.000 description 2
VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 2
YMRNZNHFJGQDCB-UHFFFAOYSA-N 2-amino-3-phenylbenzoic acid Chemical compound NC1=C(C(O)=O)C=CC=C1C1=CC=CC=C1 YMRNZNHFJGQDCB-UHFFFAOYSA-N 0.000 description 2
LGERKUYJCZOBTB-UHFFFAOYSA-N 2-hydroxy-5-phenylbenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C=CC=CC=2)=C1 LGERKUYJCZOBTB-UHFFFAOYSA-N 0.000 description 2
RSQBNHDRXUMNPM-UHFFFAOYSA-N 3,4-dihydro-2h-phosphole;hydroiodide Chemical compound I.C1CC=PC1 RSQBNHDRXUMNPM-UHFFFAOYSA-N 0.000 description 2
UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 2
NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 2
SHGAZHPCJJPHSC-CDMOMSTLSA-N 9,13-cis-Retinoic acid Chemical compound OC(=O)\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-CDMOMSTLSA-N 0.000 description 2
102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
206010002023 Amyloidoses Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
229920001268 Cholestyramine Polymers 0.000 description 2
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 2
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
229920002905 Colesevelam Polymers 0.000 description 2
229920002911 Colestipol Polymers 0.000 description 2
102000016550 Complement Factor H Human genes 0.000 description 2
108010053085 Complement Factor H Proteins 0.000 description 2
229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 2
229930105110 Cyclosporin A Natural products 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108010011459 Exenatide Proteins 0.000 description 2
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
229940124036 Hydrolase inhibitor Drugs 0.000 description 2
102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
206010022773 Intracranial pressure increased Diseases 0.000 description 2
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
108010019598 Liraglutide Proteins 0.000 description 2
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
206010029113 Neovascularisation Diseases 0.000 description 2
JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 2
208000001140 Night Blindness Diseases 0.000 description 2
102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
241000288906 Primates Species 0.000 description 2
206010038848 Retinal detachment Diseases 0.000 description 2
208000032430 Retinal dystrophy Diseases 0.000 description 2
108091006614 SLC10A2 Proteins 0.000 description 2
206010039729 Scotoma Diseases 0.000 description 2
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
208000000208 Wet Macular Degeneration Diseases 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
229960002632 acarbose Drugs 0.000 description 2
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
229960001466 acetohexamide Drugs 0.000 description 2
VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229960005339 acitretin Drugs 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
210000001789 adipocyte Anatomy 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 2
230000003941 amyloidogenesis Effects 0.000 description 2
230000001772 anti-angiogenic effect Effects 0.000 description 2
229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
235000008714 apigenin Nutrition 0.000 description 2
XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 2
229940117893 apigenin Drugs 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
229960000516 bezafibrate Drugs 0.000 description 2
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000004700 cellular uptake Effects 0.000 description 2
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
229960001761 chlorpropamide Drugs 0.000 description 2
230000001906 cholesterol absorption Effects 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
229960002174 ciprofibrate Drugs 0.000 description 2
229960001214 clofibrate Drugs 0.000 description 2
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
235000017471 coenzyme Q10 Nutrition 0.000 description 2
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
229960000674 colesevelam hydrochloride Drugs 0.000 description 2
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
229960002577 colestipol hydrochloride Drugs 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000001727 diffuse idiopathic skeletal hyperostosis Diseases 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000002222 downregulating effect Effects 0.000 description 2
229960002017 echothiophate Drugs 0.000 description 2
BJOLKYGKSZKIGU-UHFFFAOYSA-N ecothiopate Chemical compound CCOP(=O)(OCC)SCC[N+](C)(C)C BJOLKYGKSZKIGU-UHFFFAOYSA-N 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
229960001519 exenatide Drugs 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229960002297 fenofibrate Drugs 0.000 description 2
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
235000021323 fish oil Nutrition 0.000 description 2
229960004369 flufenamic acid Drugs 0.000 description 2
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
229960003627 gemfibrozil Drugs 0.000 description 2
230000007614 genetic variation Effects 0.000 description 2
229960000346 gliclazide Drugs 0.000 description 2
229960004346 glimepiride Drugs 0.000 description 2
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
229960001381 glipizide Drugs 0.000 description 2
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
238000007446 glucose tolerance test Methods 0.000 description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
239000004093 hydrolase inhibitor Substances 0.000 description 2
201000008980 hyperinsulinism Diseases 0.000 description 2
201000006122 hypervitaminosis A Diseases 0.000 description 2
238000005286 illumination Methods 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
229950005809 implitapide Drugs 0.000 description 2
230000006872 improvement Effects 0.000 description 2
210000002660 insulin-secreting cell Anatomy 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
201000009941 intracranial hypertension Diseases 0.000 description 2
238000013532 laser treatment Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
229960002701 liraglutide Drugs 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
239000003475 metalloproteinase inhibitor Substances 0.000 description 2
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
229960003105 metformin Drugs 0.000 description 2
CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 2
229940084921 micronized glyburide Drugs 0.000 description 2
229960001110 miglitol Drugs 0.000 description 2
229960003574 milrinone Drugs 0.000 description 2
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
229960000698 nateglinide Drugs 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000003900 neurotrophic factor Substances 0.000 description 2
229960000916 niflumic acid Drugs 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
235000020660 omega-3 fatty acid Nutrition 0.000 description 2
229940012843 omega-3 fatty acid Drugs 0.000 description 2
239000006014 omega-3 oil Substances 0.000 description 2
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
229960001243 orlistat Drugs 0.000 description 2
235000012658 paprika extract Nutrition 0.000 description 2
239000001688 paprika extract Substances 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
230000016732 phototransduction Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
229960005095 pioglitazone Drugs 0.000 description 2
230000032361 posttranscriptional gene silencing Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000004224 protection Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
230000002040 relaxant effect Effects 0.000 description 2
229960002354 repaglinide Drugs 0.000 description 2
108010089504 retinol-palmitate esterase Proteins 0.000 description 2
WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 2
238000012552 review Methods 0.000 description 2
229960004586 rosiglitazone Drugs 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000009528 severe injury Effects 0.000 description 2
AZLXCBPKSXFMET-UHFFFAOYSA-M sodium 4-[(4-sulfophenyl)diazenyl]naphthalen-1-olate Chemical compound [Na+].C12=CC=CC=C2C(O)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 AZLXCBPKSXFMET-UHFFFAOYSA-M 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 2
229950004704 tesaglitazar Drugs 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
238000000015 thermotherapy Methods 0.000 description 2
229930003799 tocopherol Natural products 0.000 description 2
235000010384 tocopherol Nutrition 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
229960002277 tolazamide Drugs 0.000 description 2
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
229960005371 tolbutamide Drugs 0.000 description 2
CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 2
229950004514 torcetrapib Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
229940035722 triiodothyronine Drugs 0.000 description 2
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
229940035936 ubiquinone Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
150000002266 vitamin A derivatives Chemical class 0.000 description 2
235000020797 vitamin A status Nutrition 0.000 description 2
210000004127 vitreous body Anatomy 0.000 description 2
208000000318 vitreous detachment Diseases 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
GVOIABOMXKDDGU-XRODXAHISA-N (3S,3'S,5R,5'R)-3,3'-dihydroxy-kappa,kappa-carotene-6,6'-dione Chemical compound O=C([C@@]1(C)C(C[C@H](O)C1)(C)C)/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C GVOIABOMXKDDGU-XRODXAHISA-N 0.000 description 1
GVOIABOMXKDDGU-LOFNIBRQSA-N (3S,3'S,5R,5'R)-3,3'-dihydroxy-kappa,kappa-carotene-6,6'-dione Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(=O)C1(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C GVOIABOMXKDDGU-LOFNIBRQSA-N 0.000 description 1
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
108030006129 11-cis-retinol dehydrogenases Proteins 0.000 description 1
PUMKBBIQQGIUJU-UHFFFAOYSA-N 2,6-dichloro-3-phenylbenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC(C=2C=CC=CC=2)=C1Cl PUMKBBIQQGIUJU-UHFFFAOYSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
XWULCDOSZPRLEQ-QHLGVNSISA-N 2-[(1e,3e,5e,7e)-9-methoxy-3,7-dimethylnona-1,3,5,7-tetraenyl]-1,3,3-trimethylcyclohexene Chemical compound COC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XWULCDOSZPRLEQ-QHLGVNSISA-N 0.000 description 1
VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
MRHZFYDIPYOCQF-UHFFFAOYSA-N 2-fluoro-3-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1F MRHZFYDIPYOCQF-UHFFFAOYSA-N 0.000 description 1
CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
DXGGDMSNCNNMOK-KNZSRCDBSA-N 3,5,5-trimethyl-4-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-3,7,12,16-tetramethyl-18-(2,5,5-trimethyl-3,4-dioxocyclopenten-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclopent-3-ene-1,2-dione Chemical compound CC=1C(=O)C(=O)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)C(=O)C1(C)C DXGGDMSNCNNMOK-KNZSRCDBSA-N 0.000 description 1
NXAGTQRRYZTDKV-UHFFFAOYSA-N 3,5-dimethyl-1-prop-2-enylpyrazole Chemical compound CC=1C=C(C)N(CC=C)N=1 NXAGTQRRYZTDKV-UHFFFAOYSA-N 0.000 description 1
UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
JHYCFVHKUCPYKB-UHFFFAOYSA-N 3-fluoro-4-(2-fluorophenyl)benzoic acid Chemical compound FC1=CC(C(=O)O)=CC=C1C1=CC=CC=C1F JHYCFVHKUCPYKB-UHFFFAOYSA-N 0.000 description 1
KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
HJODQHMIUQOVJF-UHFFFAOYSA-N 5,5,6-trichloro-2-(3-chlorophenyl)cyclohexa-1,3-diene Chemical group C1=CC(Cl)(Cl)C(Cl)C=C1C1=CC=CC(Cl)=C1 HJODQHMIUQOVJF-UHFFFAOYSA-N 0.000 description 1
PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
LFRHISOKBMDTDQ-UHFFFAOYSA-N 5-(2-fluorophenyl)-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC=CC=2)F)=C1 LFRHISOKBMDTDQ-UHFFFAOYSA-N 0.000 description 1
JDYKLEDOXBYSTI-UHFFFAOYSA-N 5-(3,5-dichlorophenyl)-2-hydroxybenzoic acid Chemical compound OC(=O)c1cc(ccc1O)-c1cc(Cl)cc(Cl)c1 JDYKLEDOXBYSTI-UHFFFAOYSA-N 0.000 description 1
CUXSCHTUWINJSV-UHFFFAOYSA-N 5-(4-fluorophenyl)-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C=CC(F)=CC=2)=C1 CUXSCHTUWINJSV-UHFFFAOYSA-N 0.000 description 1
101150039555 ABCA4 gene Proteins 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
101710129138 ATP synthase subunit 9, mitochondrial Proteins 0.000 description 1
101710168506 ATP synthase subunit C, plastid Proteins 0.000 description 1
101710114069 ATP synthase subunit c Proteins 0.000 description 1
101710197943 ATP synthase subunit c, chloroplastic Proteins 0.000 description 1
101710187091 ATP synthase subunit c, sodium ion specific Proteins 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
MKGRMAIAGDEUTL-XYCHTSNDSA-N Actinioerythrol Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)C2(C)C MKGRMAIAGDEUTL-XYCHTSNDSA-N 0.000 description 1
241001227559 Airapus Species 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102100026663 All-trans-retinol dehydrogenase [NAD(+)] ADH7 Human genes 0.000 description 1
KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
102000001049 Amyloid Human genes 0.000 description 1
108010094108 Amyloid Proteins 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
102000004452 Arginase Human genes 0.000 description 1
108700024123 Arginases Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
101710117545 C protein Proteins 0.000 description 1
229930182476 C-glycoside Natural products 0.000 description 1
150000000700 C-glycosides Chemical class 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
208000004434 Calcinosis Diseases 0.000 description 1
102100029968 Calreticulin Human genes 0.000 description 1
108090000549 Calreticulin Proteins 0.000 description 1
VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
GVOIABOMXKDDGU-SUKXYCKUSA-N Capsorubin Natural products O=C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C(=O)[C@@]1(C)C(C)(C)C[C@H](O)C1)\C)/C)\C)/C)[C@@]1(C)C(C)(C)C[C@H](O)C1 GVOIABOMXKDDGU-SUKXYCKUSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102100028892 Cardiotrophin-1 Human genes 0.000 description 1
102000007768 Cellular Retinol-Binding Proteins Human genes 0.000 description 1
108010021988 Cellular Retinol-Binding Proteins Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
241000254173 Coleoptera Species 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
239000005751 Copper oxide Substances 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
102000016680 Dioxygenases Human genes 0.000 description 1
108010028143 Dioxygenases Proteins 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
102000002494 Endoribonucleases Human genes 0.000 description 1
108010093099 Endoribonucleases Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
102000042092 Glucose transporter family Human genes 0.000 description 1
108091052347 Glucose transporter family Proteins 0.000 description 1
206010018498 Goitre Diseases 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101100161494 Homo sapiens ABCA4 gene Proteins 0.000 description 1
101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
101000772194 Homo sapiens Transthyretin Proteins 0.000 description 1
102100026020 Hormone-sensitive lipase Human genes 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
101150022794 IDS2 gene Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000032578 Inherited retinal disease Diseases 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
102100033356 Lecithin retinol acyltransferase Human genes 0.000 description 1
229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
206010026865 Mass Diseases 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
101710170181 Metalloproteinase inhibitor Proteins 0.000 description 1
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 description 1
108050006579 Metalloproteinase inhibitor 4 Proteins 0.000 description 1
241000237852 Mollusca Species 0.000 description 1
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
208000023178 Musculoskeletal disease Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
101710193937 Protein hit Proteins 0.000 description 1
208000002607 Pseudarthrosis Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
102000018822 Retinal Dehydrogenase Human genes 0.000 description 1
108010027691 Retinal dehydrogenase Proteins 0.000 description 1
206010057430 Retinal injury Diseases 0.000 description 1
102100038053 Retinol dehydrogenase 5 Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
208000032023 Signs and Symptoms Diseases 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010041591 Spinal osteoarthritis Diseases 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
208000034972 Sudden Infant Death Diseases 0.000 description 1
206010042440 Sudden infant death syndrome Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102000003673 Symporters Human genes 0.000 description 1
108090000088 Symporters Proteins 0.000 description 1
108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108060008539 Transglutaminase Proteins 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical class O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
CVLZFLZQLXYEMO-UHFFFAOYSA-N [4-(3,5-dichlorophenyl)phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C1=CC(Cl)=CC(Cl)=C1 CVLZFLZQLXYEMO-UHFFFAOYSA-N 0.000 description 1
210000000579 abdominal fat Anatomy 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229960002105 amrinone Drugs 0.000 description 1
RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
238000002583 angiography Methods 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001896 anti-amyloidogenic effect Effects 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
DFMMVLFMMAQXHZ-CMGSAFQJSA-N apocarotenal Chemical compound O=CC(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C=CC1=C(C)CCCC1(C)C DFMMVLFMMAQXHZ-CMGSAFQJSA-N 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
235000013793 astaxanthin Nutrition 0.000 description 1
239000001168 astaxanthin Substances 0.000 description 1
MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
229940022405 astaxanthin Drugs 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
210000003403 autonomic nervous system Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008436 biogenesis Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000503 bisacodyl Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
229940055416 blueberry extract Drugs 0.000 description 1
235000019216 blueberry extract Nutrition 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
210000001775 bruch membrane Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
230000002308 calcification Effects 0.000 description 1
235000012682 canthaxanthin Nutrition 0.000 description 1
239000001659 canthaxanthin Substances 0.000 description 1
229940008033 canthaxanthin Drugs 0.000 description 1
235000018889 capsanthin Nutrition 0.000 description 1
WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
235000009132 capsorubin Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
108010041776 cardiotrophin 1 Proteins 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
208000036319 cervical spondylosis Diseases 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
230000004456 color vision Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
210000002777 columnar cell Anatomy 0.000 description 1
229960005527 combretastatin A-4 phosphate Drugs 0.000 description 1
WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
229910000431 copper oxide Inorganic materials 0.000 description 1
206010011005 corneal dystrophy Diseases 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000895 deafness Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
229960003933 dorzolamide Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
230000002616 endonucleolytic effect Effects 0.000 description 1
229940066758 endopeptidases Drugs 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
229960002199 etretinate Drugs 0.000 description 1
239000003777 experimental drug Substances 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
208000012955 familial cardiomyopathy Diseases 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005243 fluidization Methods 0.000 description 1
229940043075 fluocinolone Drugs 0.000 description 1
238000002189 fluorescence spectrum Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
201000006321 fundus dystrophy Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
201000003872 goiter Diseases 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
102000056556 human TTR Human genes 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000036039 immunity Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000017532 inherited retinal dystrophy Diseases 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000010039 intracellular degradation Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
230000004140 ketosis Effects 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
108010084957 lecithin-retinol acyltransferase Proteins 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
102000019758 lipid binding proteins Human genes 0.000 description 1
210000004446 longitudinal ligament Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000012661 lycopene Nutrition 0.000 description 1
239000001751 lycopene Substances 0.000 description 1
229960004999 lycopene Drugs 0.000 description 1
OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229960003803 meclofenamic acid Drugs 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229960003464 mefenamic acid Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000037345 metabolism of vitamins Effects 0.000 description 1
229940126170 metalloproteinase inhibitor Drugs 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
229960004023 minocycline Drugs 0.000 description 1
229960005127 montelukast Drugs 0.000 description 1
ISYPMTHOLIXZHJ-UHFFFAOYSA-N motexafin lutetium Chemical compound [Lu].CC(O)=O.CC(O)=O.C1=NC2=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C2N=CC(C(=C2CCCO)C)=NC2=CC(C(CC)=C2CC)=NC2=CC2=C(CCCO)C(C)=C1N2 ISYPMTHOLIXZHJ-UHFFFAOYSA-N 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229960004398 nedocromil Drugs 0.000 description 1
RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
238000002823 phage display Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000006552 photochemical reaction Methods 0.000 description 1
230000008832 photodamage Effects 0.000 description 1
230000003711 photoprotective effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229960004293 porfimer sodium Drugs 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
229960004583 pranlukast Drugs 0.000 description 1
UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
229950003608 prinomastat Drugs 0.000 description 1
YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
229960003876 ranibizumab Drugs 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000026304 regulation of glucose transport Effects 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
230000009712 regulation of translation Effects 0.000 description 1
230000013878 renal filtration Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
230000004243 retinal function Effects 0.000 description 1
210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
108010035291 retinol dehydrogenase Proteins 0.000 description 1
125000002523 retinol group Chemical group 0.000 description 1
201000007714 retinoschisis Diseases 0.000 description 1
108010045122 retinyl esterase Proteins 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000004358 rod cell outer segment Anatomy 0.000 description 1
MCTOGTBIQBEIBZ-RHJKTMSGSA-K rostaporfin Chemical compound CCOC(=O)C([C@]1([C@H]2C)CC)=CC3=C1N([Sn](N14)(Cl)Cl)C2=CC(C(=C2C)CC)=NC2=CC1=C(CC)C(C)=C4C=C1C(CC)=C(C)C3=N1 MCTOGTBIQBEIBZ-RHJKTMSGSA-K 0.000 description 1
229950005932 rostaporfin Drugs 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
238000002323 scanning near-field ellipsometric microscopy Methods 0.000 description 1
230000037390 scarring Effects 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000004055 small Interfering RNA Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000020712 soy bean extract Nutrition 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000005801 spondylosis Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000004500 stellate cell Anatomy 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
229950010924 talaporfin Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
150000003505 terpenes Chemical group 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940124598 therapeutic candidate Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
102000003601 transglutaminase Human genes 0.000 description 1
201000007905 transthyretin amyloidosis Diseases 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
229960003895 verteporfin Drugs 0.000 description 1
230000004304 visual acuity Effects 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
208000027121 wild type ATTR amyloidosis Diseases 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
235000008210 xanthophylls Nutrition 0.000 description 1
150000003735 xanthophylls Chemical class 0.000 description 1
229960004764 zafirlukast Drugs 0.000 description 1
125000001695 zeaxanthin group Chemical group 0.000 description 1
229960005332 zileuton Drugs 0.000 description 1
MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1